Fig. 5

FRα CAR T cells preferentially lyse tumor cells overexpressing FRα. a The MDA-231 cell line was engineered to overexpress FRα (MDA-231.FRα). b FRα CAR T cells T cells lyse MDA-231.FRα and SKOV3 more efficiently compared to MDA-231 cells. c MDA-231 cells were engineered to express ~90 % GFP (MDA-231.GFP). MDA-231.GFP cells were then mixed with MDA-231.FRα cells at a 1:1 ratio (~50 % GFP expression). The mixed cells were treated with either UNT or FRα CAR T cells at a 3:1 of E/T ratio for 24 h. UNT T cell treatment had no impact on the mixed tumor cell (~50 % GFP expression), whereas treatment with FRα CAR T cells increased the number of GFP (+)-engineered tumor cells (~85 % GFP expression)